Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York. more
Time Frame | DRUG | Sector | S&P500 |
---|---|---|---|
1-Week Return | 6.4% | -3.39% | 0.2% |
1-Month Return | 9.11% | -1.92% | 2.72% |
3-Month Return | 2981.4% | -10.54% | 7.31% |
6-Month Return | 3759.22% | -4.47% | 10.44% |
1-Year Return | 2567.79% | 4.06% | 27.53% |
3-Year Return | 138.74% | 0.94% | 30.88% |
5-Year Return | 47.22% | 36.67% | 89.21% |
Sep '19 | Sep '20 | Sep '21 | Sep '22 | Sep '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Cost of Revenue | - | - | - | 6.04K | 72.45K | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":8.33,"profit":true},{"date":"2023-09-30","value":100,"profit":true}] |
Gross Profit | - | - | - | (6.04K) | (72.45K) | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":-603700,"profit":false},{"date":"2023-09-30","value":-7245000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Operating Expenses | 78.72K | 469.36K | 8.60M | 14.73M | 7.21M | [{"date":"2019-09-30","value":0.53,"profit":true},{"date":"2020-09-30","value":3.19,"profit":true},{"date":"2021-09-30","value":58.41,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":48.97,"profit":true}] |
Operating Income | (78.72K) | (469.36K) | (8.76M) | (14.74M) | (7.21M) | [{"date":"2019-09-30","value":-7872000,"profit":false},{"date":"2020-09-30","value":-46935800,"profit":false},{"date":"2021-09-30","value":-875855300,"profit":false},{"date":"2022-09-30","value":-1474216400,"profit":false},{"date":"2023-09-30","value":-721493300,"profit":false}] |
Total Non-Operating Income/Expense | - | (16.59K) | 89.13K | (232.93K) | (157.29K) | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":-18.61,"profit":false},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":-261.35,"profit":false},{"date":"2023-09-30","value":-176.48,"profit":false}] |
Pre-Tax Income | (78.72K) | (480.38K) | (8.65M) | (14.96M) | (7.37M) | [{"date":"2019-09-30","value":-7871700,"profit":false},{"date":"2020-09-30","value":-48037700,"profit":false},{"date":"2021-09-30","value":-865076300,"profit":false},{"date":"2022-09-30","value":-1496494100,"profit":false},{"date":"2023-09-30","value":-737222500,"profit":false}] |
Income Taxes | (236.15) | 5.57K | (135.43K) | 222.78K | (14.19K) | [{"date":"2019-09-30","value":-0.11,"profit":false},{"date":"2020-09-30","value":2.5,"profit":true},{"date":"2021-09-30","value":-60.79,"profit":false},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":-6.37,"profit":false}] |
Income After Taxes | - | (485.94K) | (8.52M) | (15.19M) | (7.36M) | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":-48594500,"profit":false},{"date":"2021-09-30","value":-851532900,"profit":false},{"date":"2022-09-30","value":-1518771800,"profit":false},{"date":"2023-09-30","value":-735803600,"profit":false}] |
Income From Continuous Operations | - | (480.38K) | (8.65M) | (14.96M) | (7.37M) | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":-48037700,"profit":false},{"date":"2021-09-30","value":-865076300,"profit":false},{"date":"2022-09-30","value":-1496494100,"profit":false},{"date":"2023-09-30","value":-737222500,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Net Income | (78.72K) | (485.94K) | (8.52M) | (15.19M) | (7.37M) | [{"date":"2019-09-30","value":-7871700,"profit":false},{"date":"2020-09-30","value":-48594500,"profit":false},{"date":"2021-09-30","value":-851532900,"profit":false},{"date":"2022-09-30","value":-1518771800,"profit":false},{"date":"2023-09-30","value":-737222500,"profit":false}] |
EPS (Diluted) | - | - | (0.61) | (0.94) | (0.77) | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":-61.05,"profit":false},{"date":"2022-09-30","value":-94.37,"profit":false},{"date":"2023-09-30","value":-76.59,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
DRUG | |
---|---|
Cash Ratio | 34.65 |
Current Ratio | 35.08 |
Quick Ratio | 35.17 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
DRUG | |
---|---|
ROA (LTM) | -28.86% |
ROE (LTM) | -51.80% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
DRUG | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.03 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.97 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
DRUG | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 64.71 |
Price/FCF | 1147 |
EV/R | 0.00 |
EV/Ebitda | NM |
Bright Minds Biosciences Inc (DRUG) share price today is $41.4
Yes, Indians can buy shares of Bright Minds Biosciences Inc (DRUG) on Vested. To buy Bright Minds Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DRUG stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Bright Minds Biosciences Inc (DRUG) via the Vested app. You can start investing in Bright Minds Biosciences Inc (DRUG) with a minimum investment of $1.
You can invest in shares of Bright Minds Biosciences Inc (DRUG) via Vested in three simple steps:
The 52-week high price of Bright Minds Biosciences Inc (DRUG) is $79.02. The 52-week low price of Bright Minds Biosciences Inc (DRUG) is $0.93.
The price-to-earnings (P/E) ratio of Bright Minds Biosciences Inc (DRUG) is
The price-to-book (P/B) ratio of Bright Minds Biosciences Inc (DRUG) is 64.71
The dividend yield of Bright Minds Biosciences Inc (DRUG) is 0.00%
The market capitalization of Bright Minds Biosciences Inc (DRUG) is $275.39M
The stock symbol (or ticker) of Bright Minds Biosciences Inc is DRUG